Article
Oncology
John N. Staffurth, Joanne S. Haviland, Anna Wilkins, Isabel Syndikus, Vincent Khoo, David Bloomfield, Chris Parker, John Logue, Christopher Scrase, Alison Birtle, Zafar Malik, Miguel Panades, Chinnamani Eswar, John Graham, Martin Russell, Catherine Ferguson, Joe M. O'Sullivan, Clare A. Cruickshank, David Dearnaley, Emma Hall
Summary: The study found that moderate hypofractionated radiotherapy was as safe as standard radiotherapy in terms of bowel, urinary, and sexual problems over a 5-year follow-up period, confirming its status as the standard of care for men with intermediate-risk prostate cancer.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Angela Lamarca, Daniel H. Palmer, Harpreet Singh Wasan, Paul J. Ross, Yuk Ting Ma, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Tim Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David Ryder, John Ramage, Linda M. Davies, John A. Bridgewater, Juan W. Valle
Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.
Article
Critical Care Medicine
Robert S. Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Modulakgotla Sebe, Morongwe Likoti, Vinodh A. Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A. Ahidjo, Mboyo D. T. Vangu, Gavin Churchyard
Summary: This study conducted a phase 2 clinical trial in South Africa to evaluate the safety and preliminary efficacy of four host-directed therapies for tuberculosis. The results showed that CC-11050 and everolimus as adjunctive therapies have the potential benefits for tuberculosis patients, increasing the recovery of FEV1.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Oncology
Xiaofeng Chen, Xiang Xu, Danping Wang, Jinyuan Liu, Jing Sun, Mingjie Lu, Rui Wang, Bingqing Hui, Xiaofei Li, Chenchen Zhou, Min Wang, Tianzhu Qiu, Shiyun Cui, Nana Sun, Yang Li, Fufeng Wang, Cuicui Liu, Yang Shao, Jinhua Luo, Yanhong Gu
Summary: This open-label, single-arm phase 2 trial demonstrated that the neoadjuvant treatment of Chinese patients with esophageal squamous cell carcinoma showed good safety and feasibility.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medicine, General & Internal
Alexandre Mebazaa, Beth Davison, Ovidiu Chioncel, Alain Cohen-Solal, Rafael Diaz, Gerasimos Filippatos, Marco Metra, Piotr Ponikowski, Karen Sliwa, Adriaan A. Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Albertino Damasceno, Hadiza Saidu, Etienne Gayat, Peter S. Pang, Jelena Celutkiene, Gad Cotter
Summary: This study aimed to investigate the impact of guideline-directed medical therapy dose and up-titration pace on the efficacy and safety of patients admitted to the hospital for acute heart failure. The results showed that compared with usual care, high-intensity care significantly reduced the risk of heart failure readmission or all-cause death within 180 days.
Article
Medicine, General & Internal
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, Cristina Suarez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martin Angel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri
Summary: The study aimed to investigate the efficacy of adding atezolizumab to cabozantinib in delaying disease progression and prolonging survival in patients with metastatic renal cell carcinoma. However, the results showed that this combination did not improve clinical outcomes and led to increased toxicity, discouraging the sequential use of immune checkpoint inhibitors in these patients outside of clinical trials.
Article
Oncology
Galina Velikova, James P. Morden, Joanne S. Haviland, Charlotte Emery, Peter Barrett-Lee, Helena Earl, David Bloomfield, Adrian Murray Brunt, Peter Canney, Robert Coleman, Mark Verrill, Andrew Wardley, Gianfilippo Bertelli, Paul Ellis, Rob Stein, Judith M. Bliss, David Cameron
Summary: The study investigated the efficacy and toxicity of accelerated epirubicin and capecitabine in adjuvant chemotherapy for breast cancer. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior to CMF with less toxicity. The study also assessed the effect of chemotherapy on psychological distress, physical symptoms, and functional domains.
Article
Oncology
Yun Guan, Mingyuan Pan, Jun Yang, Qiuxia Lu, Liangfu Han, Ying Liu, Jing Li, Huaguang Zhu, Xiu Gong, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang, Enmin Wang, Xin Wang
Summary: This study aims to evaluate the efficacy and toxicity of the combination of hypofractionated stereotactic radiotherapy (HSRT) and intensity-modulated radiotherapy (IMRT) with temozolomide in GBM patients after surgery, and provide evidence for future randomized controlled trials. The study suggests that this treatment approach can improve the survival rate of patients after surgery, with acceptable toxicity and reduced treatment time.
Article
Gastroenterology & Hepatology
Ping- Hsu, Kuan-Yang Chen, Wei-Chen Tai, Jyh-Chin Yang, Feng-Woei Tsay, Yu-Hwa Liu, Chien-Lin Chen, Chia-Long Lee, Hong-Zen Yeh, Chao-Hung Kuo, Seng-Kee Chuah, Hsi-Chang Lee, Chang-Bih Shie, Sz-Iuan Shiu, John Y. Kao, Yoshio Yamaoka, David Y. Graham, Deng-Chyang Wu
Summary: This study aimed to compare the efficacy and safety of 14-day hybrid therapy, 14-day high-dose dual therapy, and 10-day bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infections. The results showed that 14-day hybrid therapy and 10-day bismuth quadruple therapy had higher eradication rates compared to 14-day high-dose dual therapy, but high-dose dual therapy had fewer adverse events.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Zhong Zheng, Dan Liu, Hanmei Lou, Li Bai, Tianshu Liu, Yunxia Li, Yuzhi Li, Qingxia Fan, Mei Feng, Haijun Zhong, Yi Huang, Ge Lou, Jing Wang, Xiaoyan Lin, Ye Chen, Ruifang An, Changzheng Li, Qi Zhou, Xin Huang, Zengqing Guo, Shubin Wang, Guiling Li, Junwei Fei, Lijing Zhu, Hong Zhu, Xiumin Li, Fenghu Li, Sihai Liao, Qinghua Min, Lei Tang, Fei Shan, Jifang Gong, Yunong Gao, Jun Zhou, Zhihao Lu, Xiaofan Li, Jianjie Li, Hui Ren, Xiaohong Liu, Hongxia Yang, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaohua Wu, Jiafu Ji
Summary: This study evaluated the safety and antitumor activity of cadonilimab monotherapy in patients with advanced solid tumors. The results showed that cadonilimab had a manageable safety profile and an encouraging tumor response rate, suggesting its potential as a treatment option for advanced solid tumors.
Article
Oncology
Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, Ana Santaballa, Andres Redondo, Laura Vidal, Nuria Lainez, Eva Guerra, Victor Rodriguez, Juan Cueva, Isabel Bover, Isabel Palacio, Maria Jesus Rubio, Mario Prieto, Jose Antonio Lopez-Guerrero, Juan Francisco Rodriguez-Moreno, Zaida Garcia-Casado, Elena Garcia-Martinez, Alvaro Taus, Ignacio Perez de Castro, Paloma Navarro, Enrique Grande
Summary: Digoxin can inhibit the growth of gastrointestinal tumor cells and induce apoptosis, indicating its potential anti-tumor effect.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Ankit Dhiman, Charles C. Vining, Hunter D. D. Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K. Roggin, Mitchell C. Posner, Osmanuddin S. Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blase Polite, Oliver S. Eng, Daniel V. T. Catenacci, Kiran K. Turaga
Summary: This study aims to investigate the role of sequential cytoreductive interventions in patients with oligometastatic foregut adenocarcinoma. Patients will undergo induction chemotherapy and then be randomized to receive either sequential curative intervention followed by maintenance chemotherapy or routine continued chemotherapy. The primary endpoint is progression-free survival (PFS), with a total of 48 patients being enrolled to detect any improvement in PFS.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Mao Yang, Yuhao Zhao, Yongsheng Li, Xuya Cui, Fatao Liu, Wenguang Wu, Xu-An Wang, Maolan Li, Yun Liu, Yingbin Liu
Summary: Gallbladder cancer (GBC) is a highly aggressive type of digestive system cancer with a poor prognosis. Afatinib, a drug targeting ErbB pathway mutations, has not been extensively studied for its efficacy in GBC treatment. This study aims to evaluate the clinical efficacy of afatinib in patients with GBC who have ErbB pathway mutations.
Article
Oncology
Olivier Bylicki, Pascale Tomasini, Gervais Radj, Florian Guisier, Isabelle Monnet, Charles Ricordel, Laurence Bigay-Game, Margaux Geier, Christos Chouaid, Catherine Daniel, Aurelie Swalduz, Anne-Claire Toffart, Helene Doubre, Jean-Michel Peloni, Diane Moreau, Fabien Subtil, Jean-Michel Grellard, Marie Castera, Benedicte Clarisse, Pedro-Henrique Martins-Lavinas, Chantal Decroisette, Laurent Greillier
Summary: This study evaluated the efficacy and safety of immune checkpoint inhibitor combined with chemotherapy and bevacizumab (when eligible) in patients with NSCLC with EGFR mutation or ALK/ROS1 fusion. The results showed that the combination approach achieved promising activity in this patient subgroup after tyrosine kinase inhibitor failure, with acceptable safety profile.
EUROPEAN JOURNAL OF CANCER
(2023)
